Archive
-
2024/05/09Allist Pharmaceuticals and Abbisko Therapeutics Jointly Announce the Initiation of a Phase 2 Clinical Study evalsuating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer
-
2023/10/30Great New | Allist Annouces that FDA Grants Breakthrough Therapy Designation to Furmonertinib in First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
2023/09/10Spotlight for Furmonertinib – NSCLC with EGFR Exon 20 Insertions Data Public at 2023 WCLC
-
2023/04/04Furmonertinib Received New Indication IND Approval by CDE – Comprehensive Cover, Global Synchronization
-
2023/03/02Fantastic News! Allist Pharmaceuticals Welcome Prestigious Scientists to Join Science Advisory Broad (SAB)
-
2023/03/01Allist Pharmaceuticals Annouced Today the Signing of a License Agreement with Abbisko Therapeutics for a New Generation of EGFR TKI, called ABK3376
-
2022/08/05Furmonertinib Published in Prestigious International Journal Once Again
-
2022/08/04Ivesa® won the "14th China Health Forum - Top 10 New Drugs (in China)”
-
2022/07/22Allist listed on “TOP 100 Hardcore Technology Enterprises in Shanghai in 2022"
-
2022/06/29Furmonertinib Approved for First-Line Treatment